Мы используем файлы cookie.
Продолжая использовать сайт, вы даете свое согласие на работу с этими файлами.
Abandoned drugs
Amibegron
Другие языки:

Amibegron

Подписчиков: 0, рейтинг: 0
Amibegron
Amibegron.svg
Clinical data
Routes of
administration		 Oral
ATC code
  • none
Legal status
Legal status
  • Development terminated
Identifiers
  • Ethyl ([(7S)-7-([(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino)-5,6,7,8-tetrahydronaphthalen-2-yl]oxy)acetate
CAS Number
PubChem CID
IUPHAR/BPS
ChemSpider
UNII
KEGG
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
Formula C22H26ClNO4
Molar mass 403.90 g·mol−1
3D model (JSmol)
  • CCOC(=O)COc3ccc1CCC(Cc1c3)NCC(O)c2cc(Cl)ccc2
  • InChI=1S/C22H26ClNO4.ClH/c1-2-27-22(26)14-28-20-9-7-15-6-8-19(11-17(15)12-20)24-13-21(25)16-4-3-5-18(23)10-16;/h3-5,7,9-10,12,19,21,24-25H,2,6,8,11,13-14H2,1H3;1H/t19-,21-;/m0./s1 checkY
  • Key:NQIZCDQCNYCVAS-RQBPZYBGSA-N checkY
  (verify)

Amibegron (SR-58,611A) was a drug developed by Sanofi-Aventis (now Sanofi) which acts as a selective agonist for the β3 adrenergic receptor. It is the first orally active β3 agonist developed that is capable of entering the central nervous system, and has antidepressant and anxiolytic effects.

On July 31, 2008, Sanofi-Aventis announced that it has decided to discontinue development of amibegron.


Новое сообщение